Red-Blue Light Therapy Mitigates Atopic Dermatitis via CD56bright NK Cell Modulation: A Mendelian Randomization Study

Area of Science:

• Immunology
• Dermatology
• Phototherapy

Background:

• Atopic Dermatitis (AD) is a chronic inflammatory skin condition.
• The role of specific Natural Killer (NK) cell subpopulations in AD pathogenesis is not fully understood.
• Investigating therapeutic strategies for AD in elderly patients is crucial.

Purpose of the Study:

• To investigate the role of CD56bright NK cells and cytokine levels in elderly patients with Atopic Dermatitis (AD).
• To evaluate the effectiveness of red-blue light therapy in treating AD in the elderly population.
• To uncover the molecular mechanisms underlying phototherapy's action in AD.

Main Methods:

• Mendelian Randomization (MR) analysis to assess causal relationships between NK cell subtypes and AD.
• Single-cell RNA sequencing (scRNA-seq) and bioinformatics analyses (GO/KEGG, PPI) to identify key genes.
• In vitro and in vivo experiments using AD mouse models with flow cytometry, ELISA, qPCR, and gene knockdown.

Main Results:

• MR analysis indicated a potential protective role for CD56bright NK cells in AD.
• scRNA-seq and pathway analyses identified NKG2D as a key gene in NK cell cytotoxicity.
• Red-blue light therapy significantly increased CD56bright NK cells and anti-inflammatory activity, reducing AD severity in mouse models.

Conclusions:

• CD56bright NK cells are genetically associated with AD and may inhibit its progression.
• Red-blue light therapy promotes CD56bright NK cell proliferation by upregulating NKG2D.
• This phototherapy effectively improves AD symptoms in elderly patients.